MDS
138
30
39
59
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
29 trials with published results (21%)
Research Maturity
59 completed trials (43% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.7%
12 terminated out of 138 trials
83.1%
-3.4% vs benchmark
6%
8 trials in Phase 3/4
49%
29 of 59 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 59 completed trials
Clinical Trials (138)
Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
Familial Investigations of Childhood Cancer Predisposition
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Pacritinib With Aza for Upfront Myelodysplastic Syndrome
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Quality of Life-Guided Transfusion in Refractory MDS or AML
National Longitudinal Cohort of Hematological Diseases
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies